AMGN·Amgen Inc.

Amgen has been added to the TrumpRx.gov platform, which will offer significant drug discounts and expands the initiative's reach. This move, alongside a recently declared $2.52 per-share second-quarter dividend, signals a strategic focus on increasing drug affordability and returning capital to shareholders. The company aims to broaden market access for key drugs like Amjevita, Aimovig, and Repatha through these initiatives. In separate developments, Amgen and Kyowa Kirin have jointly decided to discontinue all clinical trials for rocatinlimab, an anti-OX40 antibody. This decision stems from emerging safety concerns, including additional malignancy cases, which have raised scientific questions about the OX40 pathway's activity. The trials were investigating rocatinlimab for conditions such as asthma and atopic dermatitis. Investors will be watching for any further updates on the safety profile of OX40 pathway inhibitors and the market impact of Amgen's expanded drug discount programs.